Zealand Pharma stock plunges: Disappointing obesity data sends investors running
It wasn't a pretty morning for shareholders of Zealand Pharma. On Wednesday, the company released new data for their obesity drug program, and the response from investors was brutal. The Zealand Pharma share price went into a severe nosedive, at one point looking like it might lose a fifth of its value. It's the kind of day that makes you want to turn off the screen and go for a long walk to clear your head.
Why the heavy hammer?
I've spoken to a couple of equity strategists today, and the picture is pretty clear: the data simply wasn't good enough to justify the hype that had built up. In the biotech game, it's all about the graphs trending in the right direction. And here, they were off. The Zealand Pharma share price had been on a massive run beforehand, with everyone wanting a ticket on the obesity train. But with competition, particularly from Novo Nordisk, being so fierce, investors will head for the exits pretty quickly if the data doesn't meet sky-high expectations. It's brutal, but that's the nature of the beast.
One of the major Danish investment banks has already sent out an update slashing their price target. It's a classic case: expectations were ramped up so high that even a solid result would have felt like a letdown if it wasn't groundbreaking. And here, the result was more 'decent' than 'game-changing'.
Your quick guide to Zealand Pharma stock now
So, should you sell in a panic or buy on the dip? Let's do a quick,冷静 Zealand Pharma review of the situation:
- What exactly did the data show? It showed efficacy, but not enough to really challenge the established heavyweights. There were also side effects. This doesn't change the fact that Zealand has a strong pipeline, but it definitely puts a dent in the immediate excitement.
- Is the investment case dead? No. But it's wounded. The company now needs to prove they can find their own niche or improve the data in the next trial phase. That takes time.
- Short-term or long-term play? If you're a day trader, you've probably moved on. If you're putting together your own Zealand Pharma investment guide with a multi-year horizon, then a drop like this could present an opportunity. But it requires solid faith in the science and the management team.
How to use this stock in your portfolio
How to use Zealand Pharma stock sensibly? My personal rule is that biotech stocks like this should only ever make up a small part of your overall portfolio. The rest should be something a bit more boring and stable. Because when a sell-off happens like it did yesterday, you need to be able to sleep at night without checking the price every five minutes.
My best advice right now? Let the dust settle. See what the company itself has to say in the coming days, and have a good think about whether your stomach can handle this kind of wild ride. Because the Zealand Pharma share price isn't going to be a smooth journey. It's going to be a bloody rollercoaster. But for some, that's exactly what makes it interesting.